NYSE:MRKPharmaceuticals
Merck (MRK) Gains Breakthrough Therapy Designation For Lung Cancer Drug
Merck (MRK) recently presented promising phase 2 trial results for ifinatamab deruxtecan, earning Breakthrough Therapy Designation from multiple regulatory bodies, an event that coincides with the company's 4.98% share price increase last month. Positive outcomes from the CORALreef Lipids trial and new approvals in various treatments underscore Merck's commitment to advancing its portfolio in oncology and cardiovascular diseases. This aligns with a broadly positive market context where major...